Table 6 mexyl n / v film 125mg 10mg + n30 kanonfarma

Description

Composition
Active substance:
1 tablet contains: emoxypine 125 mg, pyridoxine hydrochloride 10 mg ;.
Excipients:
Calcium hydrogen phosphate dihydrate 65 mg Calcium stearate 6.7 mg, 14 mg copovidone, colloidal silica 20 mg Sodium croscarmellose 20 mg magnesium lactate dihydrate 327.6 mg Magnesium stearate 6.7 mg Hydrogenated castor oil 5 mg Cellulose microcrystalline 50 mg; composition of the film coating: Opadry White 20 mg, including: hypromellose (hydroxypropyl methylcellulose) 6.75 mg giproloza (hydroxypropylcellulose) 6.75 mg talc 4 mg titanium dioxide 2.5 mg.
Description:
Round, biconvex tablets, film-coated white or almost white. The cross section – a white or nearly white.
Product form:
Tablets, film-coated.
At 10 or 15 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 3, 6, 10 contour cell packs of 10 pills, or 1, 2, 4, 6 contour cell packs of 15 tablets together with instructions for use placed in a pile of cardboard.
Contraindications
hypersensitivity; acute hepatic and / or renal failure; pregnancy, lactation, infancy.
Carefully
Peptic ulcer and 12 duodenal ulcer.
Dosage
125 mg + 10 mg
Indications
In combination therapy: – vascular encephalopathy; – syndrome of vegetative dystonia; – tpevozhnyh states DURING nevpoticheskix and nevpozopodobnyx sostoyaniyah; – abstinentnogo sindpoma DURING alkogolizme with ppeobladaniem nevpozopodobnyx and vegetativno-sosudistyx rasstpoystv; – coronary heart disease (prevention of attacks); – soctoyaniya posle ostpoy intoksikatsii antipsixoticheskimi spedstvami; – astenicheskie sostoyaniya and takzhe for ppofilaktiki pazvitiya somaticheskix zabolevany pod vozdeystviem ekstpemalnyh faktopov and nagpyzok; – vozdeystvie ekstpemalnyx (stpessopnyh) faktopov.
Interaction with other drugs
emoxypine
Potentiates the effect of benzodiazepine anxiolytics, antiepileptics (carbamazepine), antiparkinsonian drugs (levodopa) nitrate. It reduces the toxic effects of ethanol.
pyridoxine
It enhances the effect of diuretics; attenuates levodopa activity well with cardiac glycosides (pyridoxine promotes synthesis of contractile proteins in the myocardium), with glutamic acid, and potassium and magnesium aspartate (increased resistance to hypoxia). Pyridoxine pharmaceutically incompatible with thiamine and cyanocobalamin. Isoniazid, penicillamine, cycloserine and estrogen-containing oral contraceptives weaken the effect of pyridoxine.
Overdose
emoxypine
Due to the low toxicity of overdose is unlikely. Accidental overdosing may cause drowsiness and sedation. Treatment usually is not required – the symptoms disappear on their own within a day. In severe cases, insomnia – 10 mg of nitrazepam, oxazepam 10 mg or 5 mg diazepam.
pyridoxine
High doses of pyridoxine in a short period of time (in a dose of 1 g per day) can cause a momentary appearance of the neurotoxic effects.
When receiving priridoksina at a dose exceeding 150 mg / kg of body weight are recommended to induce vomiting and take activated charcoal. Provocation emesis is most effective during the first 30 minutes after ingestion. It may be required to take emergency measures.
pharmachologic effect
Pharmacological group:
Antioxidant vitamin means +.
Pharmacological properties:
Mexyl 6® – combined formulation.
Pharmacodynamics:
Emoxypine inhibitor of free radical processes – membrane protectors having also anti-hypoxic, stress protective, neuroprotective, antiepileptic and anxiolytic action. Antioxidant preparation regulating metabolic processes in myocardium and vascular wall. The mechanism of action caused by the antioxidant and membrane properties. Inhibits lipid peroxidation increases superoksidoksidazy activity, affects the physicochemical properties of membranes, increases the content of polar lipid fractions (fosfotidilserina and fosfotidilinozita et al.) In the membrane, reduces the ratio of cholesterol / phospholipid reduces the viscosity of the lipid layer and increases membrane fluidity, activates energosinteziruyuschshie improves mitochondrial function and energy metabolism in the cells and thus protect the unit cells and the structure of their membranes. Caused by drug change in functional biological membrane activity leads to conformational changes in protein macromolecules synaptic membrane, whereupon it has a modulating effect on the activity of membrane bound enzymes, ion channels and receptor complexes, in particular, benzodiazepine, GABA acetylcholine, enhancing their ability to bind to ligands, increasing neurotransmitter activity and activation of synaptic processes.
Enhances the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in adenosine triphosphate (ATP) and creatine phosphate, activates energosinteziruyuschuyu mitochondrial function.
Increases resistance to the impact of various harmful factors in pathological conditions (shock, hypoxia and ischemia, cerebrovascular disease, intoxication with ethanol and antipsychotic drugs).
Improves cerebral metabolism and blood circulation, microcirculation and blood rheology, reduce platelet aggregation. Stabilizes the membranes of blood cells (red blood cells, and platelets), reducing the likelihood of hemolysis. It has hypolipidemic effect, reduces total cholesterol and low density lipoprotein (LDL).
It improves the functional state of ischemic myocardium, reducing the symptoms of diastolic dysfunction and systolic left ventricular (LV) and myocardial electrical instability.
In the context of the critical reduction in coronary blood flow helps to preserve the structural and functional organization of the cardiomyocyte membrane, stimulates the activity of membrane enzymes – phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports evolving during acute ischemia activation and promotes aerobic glycolysis in hypoxia recovery mitochondrial redox processes, increases the synthesis of adenosine triphosphate (ATP), creatine phosphate and other macroergs. Increases collateral blood flow to ischemic myocardium and activates energosinteziruyuschie processes in the ischemic area, thereby preserving the integrity of cardiomyocytes and maintain their functional activity.
Patients with stable angina increases exercise tolerance nitrates and anti-anginal activity, improves the rheological properties of the blood, reduces the incidence of acute coronary insufficiency.
Pyridoxine, entering the organism is phosphorylated, is converted into pyridoxal-5-phosphate, and part of the enzymes carrying out decarboxylation, transamination, and racemization of amino acids and enzymatic conversion of sulfur-containing amino acids and hydroxylated. Involved in the metabolism; necessary for normal functioning of the central and peripheral nervous system. Pyridoxine is involved in the metabolism of tryptophan, methionine, cysteine, glutamic and other amino acids. It plays an important role in the metabolism of histamine. It contributes to the normalization of lipid metabolism.
Pharmacokinetics:
Emoxypine rapidly absorbed by ingestion (period poluabsorbtsii – 0.08-1 h). The time to reach maximum concentration (TCmax) ingestion -. 0,46-0,5 h Maximum concentration (Cmax) ingestion – 50-100 ng / ml. Rapidly distributed to organs and tissues. The average retention time in the body emoxypine ingestion -. 4.9-5.2 h emoxypine metabolized in the liver by glyukuronirovaniya. 5 metabolites have been identified: 3-hydroxypyridine phosphate – is produced in the liver and involvement of alkaline phosphatase decomposes to phosphoric acid, and 3-hydroxypyridin; 2nd metabolite – a pharmacologically active, is formed in large quantities and is found in the urine 1-2 hours after administration;
Third – is displayed in large amounts in the urine; 4 th and 5 th – glyukuronkonyugaty.
The half-life when administered -. 4,7-5 hours rapidly excreted in the urine primarily as metabolites (50% for 12 hours) and a small amount – unchanged (0.3% in 12 hours). The most extensively excreted within the first 4 hours after ingestion emoxypine. excretion in the urine unchanged indicators emoxypine and metabolites have significant individual variability.
Pyridoxine is rapidly absorbed throughout the small intestine. It is metabolized in the liver to produce pharmacologically active metabolites (pyridoxal and piridoksaminofosfat). Pyridoxal phosphate binds to plasma proteins by 90%. It penetrates into all tissues; accumulates predominantly in the liver, is less – in the muscles and the central nervous system (CNS). Crosses the placenta, is secreted in breast milk. The half-life (T1 / 2) – 15-20 days. Excreted by the kidneys (intravenous injection – with 2% bile) and during hemodialysis.
Conditions of supply of pharmacies
On prescription.
side effects
Nausea, dry mouth, diarrhea, drowsiness, allergic reactions, hypersecretion of hydrochloric acid (HCl), numbness, appearance sense of constriction in the limbs – symptom “stocking” and “glove”, reducing lactation (sometimes it is used as a therapeutic effect).
special instructions
Effects on ability to drive vehicles and mechanisms
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside, 1 tablet 3 times a day; initial dose of 1-2 tablets 1-2 times a day with gradual increase to produce a therapeutic effect. The maximum daily dose is 6 tab / day. Duration of treatment – 2-8 weeks. If necessary, may repeat courses.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist